Teva to discontinue research for continual headache remedy
(Reuters) – Israel’s Teva Pharmaceutical Inc mentioned on Friday it could discontinue a trial testing its drug for the remedy of continual cluster headache, after an evaluation confirmed that the drug was unlikely to satisfy the research’s fundamental aim.
Cluster complications happen in cyclical patterns, or clusters, and are among the many most painful varieties of complications.
The drug, fremanezumab, is below assessment by the U.S. Meals and Drug Administration for prevention of migraines in adults and the corporate hopes to launch the drug for the dysfunction as quickly as mid-September.
Teva, which is relying on fremanezumab to assist return to development, additionally plans to proceed testing the drug for the remedy of episodic cluster complications.
“While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine,” mentioned Tushar Shah, senior vice chairman, head of worldwide specialty scientific growth at Teva.
Teva’s U.S.-listed shares fell 1.6 % to $23.four in premarket buying and selling.
Reporting by Manas Mishra in Bengaluru; Modifying by Anil D’Silva